A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

Summary

The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.

Timeline

Start

2023-07-31

Primary completion

2025-06-19

Completion

2025-06-19

Outcome

Met primary endpoint

registry analysis (superiority test); Placebo QD vs 6 mg Orforglipron QD; p <.001; LS Mean Difference (Final values) -5.28 (95% CI -7.52 to -3.03); ANCOVA NCT05931380 ↗

registry analysis (superiority test); Placebo QD vs 6 mg Orforglipron QD; p <.001; Risk Difference (RD) 30.36 (95% CI 15.09 to 45.62); Regression, Logistic NCT05931380 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Orforglipron	Small molecule	6 mg	Oral
Subject	Orforglipron	Small molecule	12 mg	Oral
Subject	Orforglipron	Small molecule	36 mg	Oral

Indications